Ezetimibe 10 mg
Choletimb, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Combination therapy with HMG-CoA reductase inhibitors:
Choletimb, administered in combination with an HMG-CoA reductase inhibitor, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Homozygous Familial Hypercholesterolemia (HoFH)
The combination of Choletimb and Statins, is indicated for, the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
Choletimb is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
Also Choletimb reduces TG and increases HDL-C in patients with hypercholesterolemia.
Prior to initiating therapy with Choletimb, secondary causes for dyslipidemia (i.e. diabetes, hypothyroidism, obstructive liver disease, chronic renal failure, and drugs that increase LDL-C and decrease HDL-C [progestins, anabolic steroids, and corticosteroids]), should be excluded or, if appropriate, treated.
There are no adequate and well-controlled studies of ezetimibe in pregnant women. Ezetimibe should be used during pregnancy only if the potential benefit justifies the risk to the fetus.
No over dosage with Choletimb have been reported in clinical studies administrated of ezetimibe, 50mg / day, to 15 healthy subjects for up to 14 days was generally well tolerated. In the event of overdose symptomatic and supportive measures should be employed.
• A box of 14 tablets, each tablet contains 10 mg ezetimibe.
• Store at room temperature, Protect from moisture.
Manufactured by Marcyrl